|Bid||822.00 x 0|
|Ask||823.00 x 0|
|Day's Range||811.50 - 830.00|
|52 Week Range||716.00 - 1,069.00|
|Beta (3Y Monthly)||0.62|
|PE Ratio (TTM)||205.00|
|Forward Dividend & Yield||0.07 (0.81%)|
|1y Target Est||N/A|
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed James (‘Jim’) Meyer as General Manager, Commercial Medicines, US, with immediate effect. Jim Meyer is an accomplished and seasoned executive with nearly 40 years of experience in the pharmaceutical industry, of which included five years at Teva Pharmaceuticals where he led the Oncology New Products Division in the US. As the Oncology Lead, he was responsible for the commercial development and launch of multiple oncology products.
Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that Foscavir (foscarnet sodium) has received approval for the treatment of HHV-6 encephalitis from the Ministry of Health, Labour and Welfare (‘MHLW’) in Japan. Approval of the new indication by the MHLW follows reimbursement received in November 2018. Foscavir is the first medicine in the world to receive approval from a Regulatory Authority for the treatment of HHV-6 encephalitis.
Clinigen Group plc (AIM:CLIN, ‘Clinigen’), the global pharmaceutical and services company, has partnered with Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR, ‘Eiger’) to launch a worldwide lonafarnib Managed Access Program for patients with Progeria and Progeroid Laminopathies. Progeria, also known as Hutchinson-Gilford Progeria Syndrome, is a rare and fatal genetic condition of accelerated aging in children that researchers believe is caused by a genetic mutation that results in an overabundance of the farnesylated aberrant protein named progerin.